



DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
X	BULGER K ET AL: "TOWARDS MORE SPECIFIC THERAPY FOR LEUKEMIA TERMINAL TRANSFERASE AS A THERAPEUTIC TARGET" LEUKEMIA RESEARCH, vol. 15, no. 5, 1991, pages 285-288, XP002366593 ISSN: 0145-2126 * the whole document * * page 285, paragraph 1 *	1-11	INV. A61B1/00
X	PATENT ABSTRACTS OF JAPAN vol. 2002, no. 05, 3 May 2002 (2002-05-03) & JP 2002 000279 A (CHUGAI BUNSHI IGAKU KENKYUSHO:KK), 8 January 2002 (2002-01-08) * abstract *	1-11	
X	CA 2 368 823 A1 (BASF AKTIENGESELLSCHAFT) 16 November 2000 (2000-11-16) * the whole document * * claim 8 *	1-11	
A	US 6 342 360 B1 (CIVELLI OLIVIER ET AL) 29 January 2002 (2002-01-29) * the whole document *	1-11	
P,X	JIANG BAOHONG ET AL: "Expression of swelling- and/or pH-regulated chloride channels (ClC-2, 3, 4 and 5) in human leukemic and normal immune cells" LIFE SCIENCES, vol. 70, no. 12, 8 February 2002 (2002-02-08), pages 1383-1394, XP002388273 ISSN: 0024-3205 * the whole document * * page 1392 * N.B. Priority not valid.	1-11	TECHNICAL FIELDS SEARCHED (IPC) G01N
----- -/-- -----			
The supplementary search report has been based on the last set of claims valid and available at the start of the search.			
Place of search The Hague		Date of completion of the search 26 January 2007	Examiner Jenkins, Gareth
CATEGORY OF CITED DOCUMENTS		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			

3
EPO FORM 1503 03.82 (P04C04)



DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
X	LAMB FRED S ET AL: "Expression of CLCN voltage-gated chloride channel genes in human blood vessels" JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, vol. 31, no. 3, March 1999 (1999-03), pages 657-666, XP002388274 ISSN: 0022-2828 * the whole document * -----	1-11	
			TECHNICAL FIELDS SEARCHED (IPC)
The supplementary search report has been based on the last set of claims valid and available at the start of the search.			
Place of search The Hague		Date of completion of the search 26 January 2007	Examiner Jenkins, Gareth
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			

3
EPO FORM 1503 03.82 (P04C04)



European Patent
Office

**INCOMPLETE SEARCH
SHEET C**

Application Number

A large, empty rectangular box with a thin black border, occupying the majority of the page. This area is intended for the search results and related information.



CLAIMS INCURRING FEES

The present European patent application comprised at the time of filing more than ten claims.

- Only part of the claims have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims and for those claims for which claims fees have been paid, namely claim(s):
- No claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims.

LACK OF UNITY OF INVENTION

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

Inventions 1-31: Claims 1-11 [partial]

The association between pain and each of the 31 proteins /
nucleic acids alluded to in claim 1 (in that order).

- All further search fees have been paid within the fixed time limit. The present European search report has been drawn up for all claims.
- As all searchable claims could be searched without effort justifying an additional fee, the Search Division did not invite payment of any additional fee.
- Only part of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the inventions in respect of which search fees have been paid, namely claims:
- 1-11 (partially - inventions 1 (gene 5677) and 13 (gene 7366))
- None of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the invention first mentioned in the claims, namely claims:



The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

Inventions 1-31: Claims 1-11 [partial]

The association between pain and each of the 31 proteins /
nucleic acids alluded to in claim 1 (in that order).

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 03 71 0764

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

26-01-2007

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
JP 2002000279 A	08-01-2002	NONE	
CA 2368823 A1	16-11-2000	AT 284693 T AU 770671 B2 AU 4559100 A BR 0010337 A CN 1360502 A CZ 20014015 A3 DE 19922443 A1 WO 0067847 A2 EP 1176963 A2 ES 2234597 T3 HU 0202399 A2 JP 2002544178 T NO 20015413 A PT 1176963 T US 2006223793 A1 US 7098214 B1 ZA 200110044 A	15-01-2005 26-02-2004 21-11-2000 13-02-2002 24-07-2002 13-02-2002 09-11-2000 16-11-2000 06-02-2002 01-07-2005 28-12-2002 24-12-2002 15-11-2001 31-05-2005 05-10-2006 29-08-2006 06-03-2003
US 6342360 B1	29-01-2002	US 2002123096 A1	05-09-2002

专利名称(译)	使用 131,148,199,12303,13906,15513,17822,302,5677,194,14393,28059,7366,12212,1981,261,12416,270,1410,137,1871治疗血液病的方法和组合物， 13051,1847,1849,15402,340,10217,837,1761,8990或13249分子		
公开(公告)号	EP1471818A4	公开(公告)日	2007-03-28
申请号	EP2003710764	申请日	2003-01-28
[标]申请(专利权)人(译)	米伦纽姆医药公司		
申请(专利权)人(译)	千年制药， INC.		
当前申请(专利权)人(译)	千年制药， INC.		
[标]发明人	CARROLL JOSEPH M HEALY AILEEN WEICH NADINE S KELLY LOUISE M		
发明人	CARROLL, JOSEPH, M. HEALY, AILEEN WEICH, NADINE, S. KELLY, LOUISE, M.		
IPC分类号	G01N33/50 A61B A61B1/00 A61K31/00 A61K39/395 A61K45/00 A61K48/00 A61P7/00 A61P7/02 A61P7/04 A61P7/06 A61P13/12 A61P33/00 A61P35/00 A61P35/02 A61P39/00 C12N5/06 C12N15/09 C12Q1/02 C12Q1/68 G01N33/15 G01N33/53 G01N33/566 G01N33/567 G01N33/94		
CPC分类号	A61P13/12 C12Q1/6883 C12Q2600/136 C12Q2600/156 C12Q2600/158 G01N33/9413 G01N2500/04 G01N2500/10		
代理机构(译)	HALL , ROBERT LEONARD		
优先权	60/354333 2002-02-04 US 60/360258 2002-02-28 US 60/364476 2002-03-15 US 60/375626 2002-04-26 US 60/386494 2002-06-06 US 60/390965 2002-06-24 US 60/392480 2002-06-28 US 60/394128 2002-07-03 US 60/399783 2002-07-31 US 60/403221 2002-08-13 US 60/407045 2002-08-30 US 60/429048 2002-11-25 US		
其他公开文献	EP1471818A2		
外部链接	Espacenet		

摘要(译)

本发明涉及诊断和治疗血液病症的方法。具体地，本发明鉴定

131,148,199,12303,13906,15513,17822,302,5677,194,14393,28059,7366,12212,1981,261,12416,270,1410,137,1871,13051,1847,1849,15402,340,10217,837,1761,8990和13249与血液疾病感觉有关的组织中的基因，相对于它们在正常或非血液疾病状态中的表达，和/或作出反应与血液病有关的操作。本发明描述了用于各种血液病症的诊断评估和预后的方法，以及用

于鉴定表现出这些病症倾向的受试者的方法。本发明还提供了鉴定能够调节血液病症的化合物的方法。本发明还提供了鉴定和治疗性使用化合物作为血液病症治疗方法。

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
X	BULGER K ET AL: "TOWARDS MORE SPECIFIC THERAPY FOR LEUKEMIA TERMINAL TRANSFERASE AS A THERAPEUTIC TARGET" LEUKEMIA RESEARCH, vol. 15, no. 5, 1991, pages 285-288, XP002366593 ISSN: 0145-2126 * the whole document * * page 285, paragraph 1 *	1-11	INV. A61B1/00
X	PATENT ABSTRACTS OF JAPAN vol. 2002, no. 65, 3 May 2002 (2002-05-03) & JP 2002 000279 A (CHUGAI SUNSHI ISAKU KENKYUSHO:KK), 8 January 2002 (2002-01-08) * abstract *	1-11	
X	CA 2 368 823 A1 (BASE AKTIENGESELLSCHAFT) 16 November 2000 (2000-11-16) * the whole document * * claim 8 *	1-11	
A	US 6 342 360 B1 (CIVELLI OLIVIER ET AL) 29 January 2002 (2002-01-29) * the whole document *	1-11	
P, X	JIANG BAOHONG ET AL: "Expression of swelling- and/or pH-regulated chloride channels (ClC-2, 3, 4 and 5) in human leukemic and normal immune cells" LIFE SCIENCES, vol. 70, no. 12, 8 February 2002 (2002-02-08), pages 1383-1394, XP002388273 ISSN: 0024-3205 * the whole document * * page 1392 * N.B. Priority not valid.	1-11	
The supplementary search report has been based on the last set of claims valid and available at the date of the search.			
Place of search		Date of completion of the search	Examiner
The Hague		26 January 2007	Jenkins, Gareth
CATEGORY OF CITED DOCUMENTS			
<ul style="list-style-type: none"> X particularly relevant if taken alone Y particularly relevant if combined with another document of the same category Z technical background 1 non relevant reference 2 intermediate document 		<ul style="list-style-type: none"> I theory or principle underlying the invention L earlier related document, but published on, or after, the filing date D document cited in the prior art L document cited for other reasons A member of the same patent family, corresponding document 	

3